Table 1 Characteristics of 194 included systemic sclerosis patients
From: Anti-carbamylated protein antibodies in systemic sclerosis
Total n = 194 | Diffuse cutaneous SSc n = 39 | Limited cutaneous SSc n = 119 | Non-cutaneous SSc n = 36 | |
|---|---|---|---|---|
Female, n (%) | 155 (80) | 26 (64) | 98 (82) | 32 (89) |
Age (years), mean (SD) | 55 (13) | 56 (14) | 54 (14) | 56 (13) |
RP duration (months), median (IQR) | 101 (46; 232) | 48 (11; 106) | 124 (42; 239) | 79 (36; 239) |
Non-RP duration (months), median (IQR) | 45 (23; 135) | 13 (6; 43) | 56 (13; 163) | 25 (6; 38) |
Smoking | ||||
• Current, n (%) | 23 (12) | 4 (10) | 14 (12) | 5 (14) |
• Former, n (%) | 84 (43) | 20 (51) | 45 (38) | 19 (53) |
• Never, n (%) | 87 (45) | 15 (39) | 60 (50) | 12 (33) |
Anti-topoisomerase antibodies, n (%) | 44 (23) | 18 (46) | 25 (21) | 2 (6) |
Anti-centromere antibodies, n (%) | 80 (41) | 2 (5) | 55 (46) | 24 (67) |
Modified Rodnan Skin Score, median (IQR) | 2 (0; 6) | 10 (6; 18) | 3 (1; 5) | - |
Cardiac involvement, n (%) | 7 (4) | 3 (8) | 2 (2) | 2 (6) |
Pulmonary arterial hypertension, n (%) | 7 (4) | 3 (8) | 4 (3) | - |
ILD on HRCT, n (%) | 86 (46) | 26 (70) | 49 (42) | 11 (32) |
Gastrointestinal symptoms, n (%) | 81 (43) | 20 (54) | 49 (42) | 12 (35) |
Calcinosis, n (%) | 41 (22) | 5 (14) | 29 (25) | 7 (21) |
Digital ulcers, n (%) | 20 (11) | 2 (5) | 16 (14) | 2 (6) |
Synovitis, n (%) | 12 (6) | 3 (8) | 7 (6) | 2 (6) |